The C-C Chemokine Receptor Type 5 pipeline drugs market research report outlays comprehensive information on the C-C Chemokine Receptor Type 5 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the C-C Chemokine Receptor Type 5 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Infectious Disease, Oncology, Central Nervous System, and Gastrointestinal which include the indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Coronavirus Disease 2019 (COVID-19), Metastatic Colorectal Cancer, Gastric Cancer, Multiple Sclerosis, Neuropathic Pain (Neuralgia), and Metabolic Dysfunction-Associated Steatohepatitis (MASH). It also reviews key players involved in C-C Chemokine Receptor Type 5 targeted therapeutics development with respective active and dormant or discontinued products.

The C-C Chemokine Receptor Type 5 pipeline targets constitutes close to 19 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, Preclinical, and Discovery stages are 1, 4, 2, 5, and 2 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 4, and 1 molecule.

C-C Chemokine Receptor Type 5 overview

C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.

For a complete picture of C-C Chemokine Receptor Type 5’s drug pipeline, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.